Michael Davidson to Cholesterol Ester Transfer Proteins
This is a "connection" page, showing publications Michael Davidson has written about Cholesterol Ester Transfer Proteins.
Connection Strength
8.521
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
Score: 0.919
-
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026 Jan; 13(1):100394.
Score: 0.896
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.888
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 12; 12(6):e70010.
Score: 0.843
-
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity. Curr Opin Lipidol. 2024 12 01; 35(6):303-309.
Score: 0.836
-
CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis. Front Endocrinol (Lausanne). 2024; 15:1359780.
Score: 0.817
-
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72.
Score: 0.366
-
Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
Score: 0.313
-
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006 Nov 07; 48(9):1774-81.
Score: 0.241
-
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026 Jul 07; 47(26):3404-3414.
Score: 0.236
-
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers. Am J Cardiovasc Drugs. 2025 Sep; 25(5):693-702.
Score: 0.219
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
Score: 0.217
-
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimers Res Ther. 2024 10 16; 16(1):228.
Score: 0.209
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 09; 64(9):1150-1164.
Score: 0.203
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
Score: 0.198
-
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022 08; 28(8):1672-1678.
Score: 0.180
-
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.
Score: 0.105
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
Score: 0.080
-
Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.
Score: 0.074
-
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):3E-9E.
Score: 0.074
-
Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
Score: 0.074
-
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.
Score: 0.074
-
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006 Nov 07; 48(9):1782-90.
Score: 0.060
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
Score: 0.054
-
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol. 2004 Jul; 19(4):374-9.
Score: 0.051
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.051
-
Biologic therapies for dyslipidemia. Curr Atheroscler Rep. 2004 Jan; 6(1):69-72.
Score: 0.049
-
The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003 Jul; 169(1):113-20.
Score: 0.048
-
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):148-155.
Score: 0.046
-
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. Int J Mol Sci. 2022 Aug 20; 23(16).
Score: 0.045
-
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
Score: 0.024
-
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012 Oct; 51(4):314-24.
Score: 0.022
-
Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia. Arterioscler Thromb. 1992 Oct; 12(10):1146-52.
Score: 0.006